Profile data is unavailable for this security.
About the company
Vigil Neuroscience, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, VGL101 (iluzanebart), is a fully human monoclonal antibody TREM2 agonist that is being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. The Company is also developing VG-3927, its orally available small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations.
- Revenue in USD (TTM)0.00
- Net income in USD-83.84m
- Incorporated2020
- Employees64.00
- LocationVigil Neuroscience Inc100 Forge Road, Suite 700WATERTOWN 02472United StatesUSA
- Phone+1 (857) 254-4445
- Websitehttps://www.vigilneuro.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiff Oncology Inc | 665.00k | -40.88m | 127.55m | 31.00 | -- | 2.39 | -- | 191.80 | -0.9142 | -0.9142 | 0.0149 | 1.15 | 0.0081 | -- | 2.17 | 21,451.61 | -49.98 | -31.24 | -57.60 | -33.56 | -- | -- | -6,143.91 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| Sagimet Biosciences Inc | 2.00m | -29.25m | 127.65m | 10.00 | -- | 0.6904 | -- | 63.83 | -1.18 | -1.18 | 0.078 | 5.74 | 0.019 | -- | -- | 200,000.00 | -27.79 | -- | -29.32 | -- | -- | -- | -1,462.55 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
| Puma Biotechnology Inc | 219.14m | 8.72m | 128.50m | 185.00 | 14.31 | 2.62 | 6.33 | 0.5864 | 0.183 | 0.183 | 4.56 | 1.00 | 1.08 | 7.07 | 7.38 | 1,184,557.00 | 4.30 | -12.21 | 7.24 | -20.53 | 73.08 | 78.78 | 3.98 | -11.79 | 1.23 | 1.99 | 0.6474 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
| P3 Health Partners Inc | 1.40bn | -69.48m | 129.46m | 400.00 | -- | 0.3509 | -- | 0.0923 | -0.5821 | -0.5821 | 11.56 | 1.03 | 1.56 | -- | 10.97 | 3,507,143.00 | -20.51 | -- | -110.70 | -- | 0.6223 | 0.1781 | -13.17 | -56.93 | -- | -9.67 | 0.2686 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
| TriSalus Life Sciences Inc | 24.74m | -57.21m | 129.56m | 112.00 | -- | -- | -- | 5.24 | -1.70 | -1.70 | 0.8372 | -0.8892 | 1.00 | 1.23 | 7.28 | 220,848.20 | -220.73 | -- | -2,149.76 | -- | 87.65 | -- | -219.71 | -- | 2.04 | -100.87 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| PDS Biotechnology Corp | 0.00 | -40.68m | 131.08m | 25.00 | -- | 4.23 | -- | -- | -1.23 | -1.23 | 0.00 | 0.8406 | 0.00 | -- | -- | 0.00 | -65.48 | -51.63 | -80.82 | -59.00 | -- | -- | -- | -- | -- | -21.59 | 0.4409 | -- | -- | -- | -5.11 | -- | -- | -- |
| Actuate Therapeutics Inc | -100.00bn | -100.00bn | 135.74m | 11.00 | -- | -- | -- | -- | -- | -- | -- | -1.05 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -22.74 | -- | -- | -- |
| Vigil Neuroscience Inc | 0.00 | -83.84m | 136.39m | 64.00 | -- | 1.52 | -- | -- | -2.12 | -2.12 | 0.00 | 2.27 | 0.00 | -- | -- | 0.00 | -59.07 | -- | -63.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Tenaya Therapeutics Inc | 0.00 | -120.74m | 136.48m | 140.00 | -- | 1.02 | -- | -- | -1.54 | -1.54 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -62.89 | -- | -69.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
| Kodiak Sciences Inc | 0.00 | -197.68m | 139.43m | 111.00 | -- | 0.65 | -- | -- | -3.77 | -3.77 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -39.89 | -31.73 | -44.14 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
| Context Therapeutics Inc | 0.00 | -18.57m | 139.50m | 5.00 | -- | 1.38 | -- | -- | -1.06 | -1.06 | 0.00 | 1.35 | 0.00 | -- | -- | 0.00 | -28.46 | -- | -29.68 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
| Immunic Inc | 0.00 | -95.31m | 140.52m | 77.00 | -- | 2.21 | -- | -- | -1.51 | -1.51 | 0.00 | 0.7058 | 0.00 | -- | -- | 0.00 | -108.78 | -72.09 | -141.92 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -64.86m | 141.79m | 51.00 | -- | 0.5812 | -- | -- | -1.11 | -1.11 | 0.00 | 4.06 | 0.00 | -- | -- | 0.00 | -27.82 | -- | -29.32 | -- | -- | -- | -- | -- | -- | -- | 0.1075 | -- | -- | -- | -22.20 | -- | -- | -- |
| Ventyx Biosciences Inc | 0.00 | -171.30m | 144.87m | 73.00 | -- | 0.5159 | -- | -- | -2.79 | -2.79 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -52.07 | -- | -55.27 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
| Repare Therapeutics Inc | 68.68m | -68.52m | 146.44m | 179.00 | -- | 0.719 | -- | 2.13 | -1.63 | -1.63 | 1.61 | 4.80 | 0.2558 | -- | 6.34 | 383,703.90 | -25.52 | -23.40 | -30.30 | -26.37 | -- | -- | -99.76 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
Data as of Oct 09 2024. Currency figures normalised to Vigil Neuroscience Inc's reporting currency: US Dollar USD
33.39%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Citadel Advisors LLCas of 31 Mar 2024 | 2.16m | 5.76% |
| BVF Partners LPas of 31 Mar 2024 | 1.81m | 4.83% |
| Invus Public Equities Advisors LLCas of 31 Mar 2024 | 1.81m | 4.82% |
| Sphera Funds Management Ltd.as of 31 Mar 2024 | 1.73m | 4.60% |
| Deep Track Capital LPas of 31 Mar 2024 | 1.59m | 4.24% |
| 683 Capital Management LLCas of 31 Mar 2024 | 994.90k | 2.65% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 882.05k | 2.35% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 795.08k | 2.12% |
| Rock Springs Capital Management LPas of 31 Mar 2024 | 471.96k | 1.26% |
| ArrowMark Colorado Holdings LLCas of 31 Mar 2024 | 289.46k | 0.77% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
